TABLE 3.
Registered clinical trials on the gene therapy of OA.
| Gene | Method of delivery | Number of participants | Evaluations | Phase | ClinialTrials.gov identifier | Status |
|---|---|---|---|---|---|---|
| TGF-β1 | Retrovirus, ex vivo | 12 | Safety and biological activity of TissueGene-C in degenerative arthritis patients | I | NCT00599248 | Completed |
| TGF-β1 | Retrovirus, ex vivo | 12 | Efficacy and safety of TissueGene-C in degenerative arthritis patients | I | NCT02341391 | Completed |
| TGF-β1 | Retrovirus, ex vivo | 102 | Efficacy and safety of TissueGene-C in Patients with grade 3 chronic degenerative joint disease of the knee | II | NCT01221441 | Completed |
| TGF-β1 | Retrovirus, ex vivo | 28 | Efficacy and safety of TissueGene-C in degenerative arthritis patients | II | NCT02341378 | Completed |
| TGF-β1 | Retrovirus, ex vivo | 18 | Efficacy and safety of TissueGene-C mixed with Fibrin-glue in patients with degenerative arthritis | II | NCT01825811 | Completed |
| TGF-β1 | Retrovirus, ex vivo | 54 | Efficacy and safety of TissueGene-C in degenerative arthritis patients | II | NCT01671072 | Completed |
| TGF-β1 | Retrovirus, ex vivo | 163 | Efficacy and safety of TissueGene-C in degenerative arthritis patients | III | NCT02072070 | Completed |
| TGF-β1 | Retrovirus, ex vivo | 510 | Safety and efficacy of TissueGene-C in patients with grade 2–3 knee OA | III | NCT03203330 | Active, not recruiting |
| IL-1Ra | AAV, in vivo | 9 | Safety of IA Sc-rAAV2.5IL-1Ra in patients with moderate OA of the Knee | I | NCT02790723 | Recruiting |